A new publication referencing insulin degludec appeared on September 1, 2026, in the journal Drug Metabolism and Disposition: The Biological Fate of Chemicals.
The paper is titled "Rapid and comprehensive identification of the metabolic soft spots of peptide drugs with highly cross-linked disulfide bonds by integrating established proteomic workflow with a product ion filtering strategy."
This is a publication event only. The title indicates the study addresses methods for identifying metabolic soft spots in peptide drugs that contain highly cross-linked disulfide bonds, using a proteomic workflow combined with a product ion filtering strategy.
No findings, efficacy data, or safety conclusions are described here beyond the publication title and journal information provided. Readers interested in the underlying methodology or results should consult the original article directly through the indexed source.
Insulin degludec remains an approved compound, and this entry reflects only the existence and bibliographic details of this new peer reviewed publication. For general background on insulin degludec, readers can refer to the compound overview.